We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+27.77%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$1.42B
AUM Growth
+$256M
(+22%)
Cap. Flow
+$65.4M
Cap. Flow
% of AUM
4.61%
Top 10 Holdings %
Top 10 Hldgs %
29.29%
Holding
112
New
24
Increased
30
Reduced
36
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$48.1M |
| 2 |
Replimune Group
REPL
|
+$27.8M |
| 3 |
Maravai LifeSciences
MRVI
|
+$27.3M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$25.6M |
| 5 |
Certara
CERT
|
+$22.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$51M |
| 2 |
HMSY
HMS Holdings Corp.
HMSY
|
+$18.7M |
| 3 |
Zentalis Pharmaceuticals
ZNTL
|
+$18.2M |
| 4 |
Aprea Therapeutics
APRE
|
+$17.9M |
| 5 |
BPMC
Blueprint Medicines
BPMC
|
+$16.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.8% |
| 2 | Industrials | 1.99% |
| 3 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Dyne Therapeutics
DYN
$4.71B
| – | – |
-474,301
| Closed | -$9.58M |
|
102
Emergent Biosolutions
EBS
$382M
| – | – |
-79,950
| Closed | -$8.26M |
|
|
GBIO
103
DELISTED
Generation Bio
GBIO
| – | – |
-3,500
| Closed | -$1.08M |
|
104
Humana
HUM
$45B
| – | – |
-2,666
| Closed | -$1.1M |
|
105
Outset Medical
OM
$92.5M
| – | – |
-4,652
| Closed | -$3.49M |
|
106
Taysha Gene Therapies
TSHA
$1.66B
| – | – |
-373,775
| Closed | -$8.37M |
|
|
107
Zentalis Pharmaceuticals
ZNTL
$331M
| – | – |
-556,712
| Closed | -$18.2M |
|
|
TRHC
108
DELISTED
Tabula Rasa HealthCare, Inc. Common Stock
TRHC
| – | – |
-35,177
| Closed | -$1.43M |
|
|
GBT
109
DELISTED
Global Blood Therapeutics, Inc.
GBT
| – | – |
-255,271
| Closed | -$14.1M |
|
|
CHNG
110
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| – | – |
-82,145
| Closed | -$1.19M |
|
|
HMSY
111
DELISTED
HMS Holdings Corp.
HMSY
| – | – |
-782,563
| Closed | -$18.7M |
|
|
IMMU
112
DELISTED
Immunomedics Inc
IMMU
| – | – |
-600,242
| Closed | -$51M |
|
Similar funds
RIP
LFWA
CF
WIM
MW
AFC
TGM
BIS
Sectoral Asset Management's Q4 2020 Portfolio in Review
As of Q4 2020, Sectoral Asset Management held 112 positions worth $1.42B, up 22% from $1.16B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Sectoral Asset Management deployed $65.4M of net new capital in Q4 2020, opening 24 new positions and adding to 30 existing holdings. Its largest new stake was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 90% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was Aprea Therapeutics, an estimated $17.9M trimmed.
- Sectoral Asset Management's largest Q4 2020 buy was Atea Pharmaceuticals: 1,492,090 shares worth $62.3M.
- Sectoral Asset Management added most to Tandem Diabetes Care in Q4 2020, an estimated $25.6M increase.
- Sectoral Asset Management's biggest Q4 2020 reduction was Aprea Therapeutics, cutting an estimated $17.9M.
- Sectoral Asset Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $51M.
- Sectoral Asset Management's ten largest holdings make up 29% of its $1.42B portfolio in Q4 2020.
- Sectoral Asset Management opened 24 new positions and closed 15 in Q4 2020.
- Sectoral Asset Management's portfolio value rose 22% quarter-over-quarter to $1.42B.
Based on Sectoral Asset Management's 13F filing for Q4 2020, filed 12 Feb 2021.